In early PD therapeutic trials, ∼10–15% of subjects are identified as SWEDD.4 Previous longitudinal follow‐up of SWEDD subjects suggested minimal or absent clinical or imaging PD progression.5, 16 The objective of this work was to build upon previous findings and evaluate DAT neuroimaging as an enrichment biomarker in clinical trials targeting patients with early‐stage PD. This evidence concerns the gene SLC6A3 and Parkinson disease.